Malignancies arising from the central nervous system are rare. Brain metastases, in contrast, are perhaps the most common neurologic complication of cancer. Radiotherapy, as part of combined modality therapy, continues to evolve with the advancement of stereotactic radiosurgery indications, the addition of new technologies, such as alternating electric field therapy, and mounting advances in the complex biology of these entities. The explosion of new clinical trials combined with newly discovered molecular markers suggest the beginning of a paradigm shift in the management of these challenging malignancies that will allow for future risk-stratification strategies.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.soc.2017.01.003 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!